Iradimed (IRMD) Earning Positive Media Coverage, Study Shows

Press coverage about Iradimed (NASDAQ:IRMD) has been trending positive on Friday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a news impact score of 0.28 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.4319680893128 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Separately, Zacks Investment Research raised shares of Iradimed from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $17.33.

NASDAQ IRMD opened at $14.30 on Friday. Iradimed has a 12 month low of $7.85 and a 12 month high of $15.85. The stock has a market cap of $151.65, a PE ratio of 178.75 and a beta of 1.42.

Iradimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, February 6th. The medical equipment provider reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.04. Iradimed had a return on equity of 3.03% and a net margin of 2.17%. The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.72 million. During the same quarter in the previous year, the business earned $0.11 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. sell-side analysts forecast that Iradimed will post 0.25 earnings per share for the current year.

In other Iradimed news, insider Louis S. Waldman sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $13.83, for a total value of $414,900.00. Following the completion of the transaction, the insider now owns 5,221 shares in the company, valued at approximately $72,206.43. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 60.10% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Iradimed (IRMD) Earning Positive Media Coverage, Study Shows” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://baseballnewssource.com/2018/04/06/favorable-press-coverage-somewhat-unlikely-to-affect-iradimed-irmd-share-price/2030035.html.

Iradimed Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.